HER2 positive breast cancer responded to combination therapy
A phase lll trial found that a combination of medications given after surgery was extremely effective in treating patients with HER2-positive breast cancer, which was likely to spread or return (recur).
Three years after receiving a combination of Taxotere (docetaxel), Paraplatin (carboplatin) and Herceptin (trastuzumab), 92 percent of patients with HER2-positive breast cancer were still alive with no evidence of the disease.
The researchers discovered that highly toxic chemotherapies, which have traditionally been used to treat this form of breast cancer, were unnecessary to achieve this success.
Read more from RxWiki HERE.